Primary Biliary Cirrhosis (Pbc) Treatment Market By Drug Type (Ursodeoxycholic Acid, Obeticholic Acid, Corticosteroids, Methotrexate); By Surgery (Liver Transplant); By Diagnosis Test (Blood Test, Imaging, Liver Biopsy) & By Geography-Forecast (2016- – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Primary Biliary Cirrhosis (Pbc) Treatment Market By Drug Type (Ursodeoxycholic Acid, Obeticholic Acid, Corticosteroids, Methotrexate); By Surgery (Liver Transplant); By Diagnosis Test (Blood Test, Imaging, Liver Biopsy) & By Geography-Forecast (2016- Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Primary biliary cirrhosis, also known as primary biliary cholangitis (PBC), is an autoimmune disease of the liver which is relatively rare as compared to other gastro diseases. The advanced stage of PBC is considered as cirrhosis. Identification, diagnosis and treatment differ based on the severity of PBC and patients’ condition. Several diagnosis tests are recommended including blood tests, imaging tests and liver biopsy which further encompass several test methods. The treatment includes medication approach as well as surgical approach. Medical approach includes employment of approved drugs individually or in combination including Ursodeoxycholic Acid, Corticosteroids and Methotrexate which are marketed under different brand names. Obeticholic Acid, new drug is under clinical trials and is expected to be launched in the near future.

The growth of this market is primarily attributed to increasing availability of treatment services and drugs. In addition, to drugs, liver transplantation is performed which completely prevents PBC. Establishment of diagnosis and treatment standards in the recent years boosts the overall service experience as well as treatment outcomes which propels the market growth. Driven by the aforementioned factors, this market is set to reach $XX billion by 2021, growing at a CAGR of XX% during 2016-2021.

North America held a major share of XX% in the PBC drugs market, followed by Europe and APAC. Commercialization of new drugs and expanding specialized services for liver in India and China is set to boost the market revenue in APAC region.

The key players in the PBC Drugs market include:

Sanofi S.A.
Intercept Pharmaceuticals, Inc.
Mylan N.V.
Mankind Pharmaceuticals Pvt. Ltd.

The estimates and forecasts have been derived based on various inputs from primary and secondary sources. Secondary sources such as articles, whitepapers, journals and other has helped to deliver an extensive analysis in this report. Insights related to various regulatory frameworks and clinical studies have been collected from publications by health regulatory agencies. To enhance the accuracy of the estimates, the data has been validated by conducting interviews with industry experts. This report on the PBC treatment market identifies many such insights, new product developments, besides providing a detailed analysis of the key drug companies, treatment service providers and growth potential of the market.

Please Note: The report is to be delivered in 1-2 working days after an order is placed.

Read more and order at Primary Biliary Cirrhosis (Pbc) Treatment Market By Drug Type (Ursodeoxycholic Acid, Obeticholic Acid, Corticosteroids, Methotrexate); By Surgery (Liver Transplant); By Diagnosis Test (Blood Test, Imaging, Liver Biopsy) & By Geography-Forecast (2016-